

- omeprazole in coronary artery disease. *N Engl J Med* 2010;363:1909–17.
41. Rassen J., Choudhry N., Avorn J., Schneeweiss S. Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome. *Circulation* 2009;120:2322–9.
 42. Bhurke S., Martin B., Li C. et al. Effect of the clopidogrel-proton pump inhibitor drug interaction on adverse cardiovascular events in patients with acute coronary syndrome. *Pharmacotherapy* 2012;32:809–18.
 43. Burkard T., Kaiser C., Brunner-La Rocca H. et al. Combined clopidogrel and proton pump inhibitor therapy is associated with higher cardiovascular event rates after percutaneous coronary intervention: a report from the BASKET trial. *J Intern Med* 2012;271:257–63.
 44. Ray W., Murray K., Griffin M. et al. Outcomes with concurrent use of clopidogrel and proton-pump inhibitors: a cohort study. *Ann Intern Med* 2010;152:337–45.
 45. Laine L., Hennekens C. Proton pump inhibitor and clopidogrel interaction: fact or fiction? *Am J Gastroenterol* 2010;105:34–41.
 46. Horn J., Hansten P. Methotrexate and Proton Pump Inhibitors. <http://www.pharmacytimes.com/publications/issue/2012/April2012/Methotrexate-and-Proton-Pump-Inhibitors>
 47. Mikkelsen T., Thorn C., Yang J. et al. PharmGKB summary: methotrexate pathway. *Pharmacogenet Genomics* 2011;21:679–86.
 48. Ranchon F., Vantard N., Gouraud A. et al. Suspicion of drug-drug interaction between high-dose methotrexate and proton pump inhibitors: a case report – should the practice be changed? *Chemotherapy* 2011;57:225–9.
 49. Santucci R., Leveque D., Kemmel V. et al. Severe intoxication with methotrexate possibly associated with concomitant use of proton pump inhibitors. *Anticancer Res.* 2010;30:963–5.
 50. Suzuki K., Doki K., Homma M. et al. Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy. *Br J Clin Pharmacol* 2009;67:44–9.
 51. Joerger M., Huitema A., van den Bongard H. et al. Determinants of the elimination of methotrexate and 7-hydroxy-methotrexate following high-dose infusional therapy to cancer patients. *Br J Clin Pharmacol* 2005;62:71–80.
 52. Vakily M., Amer F., Kukulka M., Andhivarothai N. Coadministration of lansoprazole and naproxen does not affect the pharmacokinetic profile of methotrexate in adult patient with rheumatoid arthritis. *J Clin Pharmacol* 2005;45:1179–86.
 53. Bezabeh S., Mackey A., Kluetz P. et al. Accumulating evidence for a drug-drug interaction between methotrexate and proton pump inhibitors. *Oncologist* 2012;17:550–4.
 54. New Safety Information: Interaction of Proton Pump Inhibitors (PPIs) with Methotrexate. Information Update. 2012–157 October 19, 2012. http://www.hc-sc.gc.ca/ahc-asc/media/advisories-avis/_2012/2012_157-eng.php
 55. Yeomans N., Tulassay Z., Juhasz L. et al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. *N Engl J Med* 1998;338:719–26.
 56. Ng F., Wong S., Lam K. et al. Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions. *Gastroenterology* 2010;138:82–8.
 57. Taha A., McCloskey C., Prasad R., Bezlyak V. Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial. *Lancet* 2009;374:119–25.
 58. Singh G., Triadafilopoulos G. Appropriate choice of proton pump inhibitor therapy in the prevention and management of NSAID-related gastrointestinal damage. *Int J Clin. Pract* 2005;59:1210–7.

Информация

Премия имени профессора Э.Р. Агабабовой

13 мая 2013 г. на церемонии открытия Съезда ревматологов России состоялось награждение победителей конкурса на соискание Премии имени профессора Э.Р. Агабабовой, присуждаемой за научные работы по изучению спондилоартритов. Премия и Диплом победителя вручены **Бочковой Анне Георгиевне** и соавторам, ФГБУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой» РАМН, Москва, — за серию работ по диагностике и лечению анкилозирующего спондилита.

Дипломами награждены:

Годзенко Алла Александровна и соавторы, ГБОУ ДПО «Российская медицинская академия последипломного образования» Минздрава России, Москва, — за работы по внескелетным проявлениям анкилозирующего спондилита;

Мясоутова Лейсан Ильдаровна и соавторы, ГБОУ ВПО «Казанский государственный медицинский университет» Минздрава России, — за работы, посвященные клинической картине и диагностике анкилозирующего спондилита.

